| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Astragalus contains two main bioactive isoflavone compounds: astragaloside and astragaloside-7-O-β-D-glucoside. To analyze the metabolites of astragaloside in a 9000 g rat liver supernatant culture system and the metabolites of astragaloside-7-O-β-D-glucoside in rat urine, this study employed high-performance liquid chromatography-diode array detector-electrospray ionization trap time-of-flight mass spectrometry (HPLC-DAD-ESI-IT-TOF-MSn). A total of 24 in vitro metabolites of astragaloside and 33 in vivo metabolites of astragaloside-7-O-β-D-glucoside were identified. In vitro metabolism revealed that monosaccharylation, pentosaccharylation, demethylation, dehydroxylation, dimerization, and trimerization are novel metabolic reactions of astragaloside; in vivo metabolism revealed that hydroxylation and hydrogenation are novel metabolic reactions of astragaloside-7-O-β-D-glucoside. In a 9000 g supernatant incubation system of rat liver, the main metabolic reactions of mangiferin were A-ring monohydroxylation, dimerization (CO coupling), dimerization (CC coupling), and dehydroxylation; in rats, the main phase I metabolic reactions of mangiferin-7-O-β-D-glucoside were deglycosylation, hydroxylation, demethylation, and dehydroxylation. Hydroxylation, dehydroxylation, and demethylation are common metabolic pathways for mangiferin and mangiferin-7-O-β-D-glucoside. Metabolites formed through these reactions, such as 8-hydroxymangiferin (S10, M10), pratercinone (5-hydroxymangiferin, S19, M27), mangiferin (S22, M28), daidzein (M22), 7,3',4'-trihydroxyisoflavone (aglycones of S13, M3, and M8), and equol (aglycones of M19 and M20), have been reported to possess numerous biological activities related to the pharmacological effects of mangiferin and mangiferin-7-O-β-D-glucoside. These findings will contribute to a deeper understanding of the metabolism and active forms of mangiferin and mangiferin-7-O-β-D-glucoside. High-performance liquid chromatography-tandem mass spectrometry (HPLC-MS(n)) was used, a method with high specificity and sensitivity, to identify the metabolites of mangiferin-7-O-β-D-glucopyranoside in vivo and in vitro in rats. Following oral administration of mangiferin-7-O-β-D-glucopyranoside, the parent compound and 12 metabolites were detected in rat urine. The parent compound and 6 metabolites were detected in rat plasma. In heart, liver, spleen, lung, and kidney samples, 6, 8, 7, 9, and 9 metabolites were identified, respectively, in addition to the parent compound. Three metabolites were found in rat intestinal flora cultures and feces, but the parent drug was not detected, indicating that the glycosidic bonds of the parent compound were broken in the intestine. In rats, the main phase I metabolic pathway of mangiferin-7-O-β-D-glucopyranoside includes deglycosylation, dehydroxylation, and demethylation; the phase II metabolic pathway includes sulfation, methylation, glucuronidation, and glycosylation (possibly). Furthermore, two metabolites commonly found in urine, plasma, and tissues were isolated from rat feces and characterized by nuclear magnetic resonance (NMR). The metabolite mangiferin showed significantly stronger antiviral activity against Coxsackievirus B3 (CVB3) and Human Immunodeficiency Virus (HIV) than mangiferin-7-O-β-D-glucopyranoside. |
|---|---|
| Toxicity/Toxicokinetics |
Interactions
Dang Gui Bu Xue Tang (DBT) is a traditional Chinese medicine decoction containing Astragalus membranaceus (AR) and Angelica sinensis (ASR). It has a history of over 800 years in China and has long been used as a health supplement to treat menopausal discomfort in women. Multiple studies have shown that the synergistic effect of Astragalus membranaceus and Angelica sinensis in this decoction enhances the pharmacological efficacy of DBT. This study aimed to investigate the roles of different traditional Chinese medicines in the transport of DBT's active ingredients. The permeability of each component on Caco-2 cell monolayers was determined using a validated RRLC-QQQ-MS/MS method. Astragalus-derived chemicals, including astragaloside IV, gentianin, and gentianin, and Angelica sinensis-derived chemicals, including ferulic acid and ligustilide, were determined by RRLC-QQQ-MS/MS. Pharmacokinetic results showed that in the presence of ASR extract, the membrane permeability of gentianin and gentianin (two major flavonoids in AR) was significantly increased: this induction may be mediated by ASR-derived ferulic acid. Conversely, AR extracts had no effect on chemical permeability. Current findings suggest that components of ASR (such as ferulic acid) can enhance the membrane permeability of AR-derived formononetin and formononetin in cultured Caco-2 cells. This article proposes the possibility of a synergistic effect of traditional Chinese medicine in DBT. |
| References |
|
| Additional Infomation |
Calycosin belongs to the 7-hydroxy isoflavone class of compounds, specifically, 7-hydroxy isoflavones with a hydroxyl group at the 3' position and a methoxy group at the 4' position. It possesses metabolic and antioxidant activities. Calycosin belongs to both the 7-hydroxy isoflavone and 4'-methoxy isoflavone classes. Functionally, it is related to isoflavones. It is the conjugate acid of Calycosin (1-). Calycosin has been reported to be found in Bowdichia virgilioides, Glycyrrhiza pallidiflora, and several other organisms with relevant data. Mechanism of Action…This study aimed to investigate the therapeutic effect of Calycosin (an active ingredient extracted from Bowdichia virgilioides) on macrophage infiltration of human umbilical vein endothelial cells (HUVECs) induced by advanced glycation end products (AGEs). A Transwell HUVEC-macrophage co-culture system was established to evaluate macrophage migration and adhesion. The expression of TGF-β1, ICAM-1, and RAGE proteins was detected by immunocytochemistry; the mRNA expression of TGF-β1, ICAM-1, and RAGE was detected by real-time quantitative PCR. The expression of estrogen receptor α, ICAM-1, and RAGE, as well as the phosphorylation status of ERK1/2 and NF-κB, were observed by immunofluorescence. Mangosteen significantly reduced AGEs-induced macrophage migration and adhesion to HUVECs. Mangosteen pretreatment significantly downregulated the protein and mRNA expression levels of TGF-β1, ICAM-1, and RAGE in HUVECs. Furthermore, mangosteen incubation significantly increased estrogen receptor expression and reversed AGEs-induced phosphorylation and nuclear translocation of ERK1/2 and NF-κB in HUVECs, while the estrogen receptor inhibitor ICI182780 inhibited this effect of mangosteen. These results indicate that gentianin can reduce AGEs-induced macrophage migration and adhesion to endothelial cells and alleviate local inflammation; moreover, this effect is achieved through the estrogen receptor-ERK1/2-NF-κB pathway.
|
| Molecular Formula |
C16H12O5
|
|---|---|
| Molecular Weight |
284.2635
|
| Exact Mass |
284.068
|
| Elemental Analysis |
C, 67.60; H, 4.26; O, 28.14
|
| CAS # |
20575-57-9
|
| Related CAS # |
20575-57-9
|
| PubChem CID |
5280448
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
536.8±50.0 °C at 760 mmHg
|
| Flash Point |
205.7±23.6 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.669
|
| LogP |
2.41
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
21
|
| Complexity |
432
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O1C([H])=C(C(C2C([H])=C([H])C(=C([H])C1=2)O[H])=O)C1C([H])=C([H])C(=C(C=1[H])O[H])OC([H])([H])[H]
|
| InChi Key |
ZZAJQOPSWWVMBI-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O5/c1-20-14-5-2-9(6-13(14)18)12-8-21-15-7-10(17)3-4-11(15)16(12)19/h2-8,17-18H,1H3
|
| Chemical Name |
7-hydroxy-3-(3-hydroxy-4-methoxyphenyl)chromen-4-one
|
| Synonyms |
Calycosin
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (~351.8 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (8.79 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5179 mL | 17.5895 mL | 35.1791 mL | |
| 5 mM | 0.7036 mL | 3.5179 mL | 7.0358 mL | |
| 10 mM | 0.3518 mL | 1.7590 mL | 3.5179 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04026321 | Completed | Drug: SQ001 625mL/day Drug: Saline 0.9% |
SSolid Tumor Refractory to Standard Therapy |
Livzon Pharmaceutical Group Inc. |
October 3, 2018 | Phase 1 |
|
|